89bio to Participate in the SVB Leerink 11ᵗʰ Annual Global Healthcare Conference
89bio, a clinical-stage biopharmaceutical company (Nasdaq: ETNB), announced its participation in the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022, at 12:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
89bio, a clinical-stage biopharmaceutical company (Nasdaq: ETNB), announced its participation in the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022, at 12:00 PM ET. The management team will engage in a fireside chat and one-on-one investor meetings. A presentation will be available via the conference portal and archived on its website.
Details
News Market Reaction – ETNB
The recorded move for ETNB in the trading session of this news was +1.32%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will participate in a fireside chat and one-on-one investor meetings at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 12:00 PM ET.
The presentation will be available through the SVB Leerink conference portal and an archived webcast will also be accessible in the investor section of 89bio’s website.
About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, pegozafermin, is a specifically engineered glycoPEGylated analog of FGF21. Pegozafermin is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com
Media Contact:
Peter Duckler
773-343-3069
pduckler@realchemistry.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.